Why is there Mounjaro left in the pen after your injection?

What the Mounjaro KwikPen's design tells us about leftover liquid

The Mounjaro KwikPen is a multi-dose, pre-filled auto-injector. Each pen contains four weekly doses, but the total volume of liquid inside is deliberately greater than four times the dose volume. This overfill is a standard pharmaceutical manufacturing practice. Eli Lilly includes it so that every one of your four injections delivers the full therapeutic amount, accounting for the needle's dead space, the plunger's mechanics, and any tiny variation in how the pen is held or pressed. The NHS tirzepatide medicines page explains that Mounjaro is injected into the fatty tissue just under the skin, and that consistency in technique matters; the overfill is part of making that consistency achievable.

When you look through the dose window after an injection, you will see the indicator has moved, that movement confirms medicine was delivered. Some liquid remains visible in the cartridge. That is expected. The pen is not faulty. Your dose is not short. This is one of those things the box does not shout about, but it is how every KwikPen leaves the factory.

For a closer look at how the pen works in practice, the Mounjaro KwikPen usage guide walks through the injection steps clearly.

Why you should never try to use the leftover liquid

The remaining medicine after your fourth dose cannot be accurately measured or safely injected. There is no dose marking on the pen for it, and the pen's plunger mechanism is not designed to deliver it in a controlled way. Attempting to use it risks delivering an undetermined amount of tirzepatide (potentially more than your prescribed dose) which increases the risk of side effects including nausea, vomiting, and in rare cases more serious reactions. The Mounjaro Summary of Product Characteristics, available via the electronic Medicines Compendium (eMC), is clear that each pen is for use over four weeks and then should be disposed of safely.

Disposal matters too. Once you have used all four doses, the pen goes into a sharps container. If you do not have one yet, a 1-litre sharps bin is a practical item to keep alongside your pen, your GP surgery or local pharmacy can advise on collection once it is full.

One thing our prescribers hear regularly: patients who have switched from another injectable medicine sometimes expect the cartridge to run dry. With Mounjaro, it will not. If you are wondering why there is some Mounjaro left in the pen after your final dose, that visible liquid at the end is a feature, not a problem.

When leftover liquid might signal a technique issue

There is one scenario worth taking seriously. If the liquid level in the dose window looks unchanged after your injection (not just a small residual amount, but the window looking much as it did before you pressed the button) that is a different situation. It can happen if the pen was not pressed firmly enough against the skin, if the button was released too quickly, or if the needle had not been attached correctly. The guidance from Lilly is to hold the injection button down and then count slowly to ten before removing the pen from the skin. Releasing too soon is the most common reason for an incomplete dose.

If you are genuinely unsure whether a dose was delivered, do not inject again without speaking to your prescriber first. Taking two doses close together is not recommended. Our clinical team at nume is available for aftercare questions seven days a week, and the FAQs page covers a number of common injection queries, including why there is liquid left in your Mounjaro pen after an injection. For anything more specific to your situation, the contact page gets you through to us directly.

For a broader look at what the pen contains and how doses are structured, the Mounjaro injection overview covers the full picture.

Putting this in context: Mounjaro's clinical programme and what it means for your pen

Tirzepatide, the medicine in Mounjaro, was studied across thousands of adults in the SURMOUNT clinical programme before receiving UK licensing. SURMOUNT-1 alone involved 2,539 participants over 72 weeks, with average body-weight reductions of around 20–21% at the highest dose. Consistency of dosing across that programme (including the pen's delivery mechanics) was central to producing those results. The overfill exists precisely because delivering a reliable dose, week after week, is what underpins that evidence.

NICE recommended tirzepatide for weight management in December 2024 (Technology Appraisal TA1026) partly on the strength of that consistency. If you have ever finished an injection and found yourself asking why there is still liquid in your Mounjaro pen, understanding that the overfill is by design is part of using the medicine the way the evidence was built around.

If you are still in the early stages of finding out whether Mounjaro is right for you, the treatment overview sets out how a consultation with our prescribers works, and the weight-loss treatments page gives broader context on the options available. Cost is a reasonable question at this stage too, and the Mounjaro pricing page covers what is included in a private prescription.

If you have questions about your current pen or your dose, speaking to a prescriber is always the right next step. Speak to our prescribers through the consultation page, where our clinical team reviews queries seven days a week.